Datasheet is currently unavailable. Try again or CONTACT US
ISG15 Antibody
Rabbit Polyclonal
8 References
200-401-438
500 µg
Lyophilized
WB, ELISA, Microarray
Human
Rabbit
Shipping info:
$50.00 to US & $70.00 to Canada for most products. Final costs are calculated at checkout.
Product Details
Anti-ISG15 (RABBIT) Antibody - 200-401-438
rabbit anti-ISG15 Antibody, G1P2 antibody, IFI 15 antibody, IFI15 antibody, Interferon alpha inducible protein antibody, Interferon induced 15 kDa protein antibody
Rabbit
Polyclonal
IgG
Target Details
ISG15 - View All ISG15 Products
Human
Recombinant Protein
This purified antibody was prepared from rabbit serum after repeated immunizations with recombinant human ISG15 protein.
This product is an IgG fraction antibody purified from monospecific antiserum by a multi-step process which includes delipidation, salt fractionation and ion exchange chromatography followed by extensive dialysis against the buffer stated above. Assay by immunoelectrophoresis resulted in a single precipitin arc against anti-Rabbit Serum.
Application Details
ELISA, WB
Microarray
- View References
This purified polyclonal antibody reacts with human ISG15 by western blot and ELISA. Although not tested, this antibody is likely functional in immunohistochemistry and immunoprecipitation. This antibody using the specified conditions may recognize other prominent intrinsic bands (UBLs or conjugates), especially at lower dilutions. An 18.5 kDa band corresponding to human ISG15 is detected. IFNα or IFNß stimulated HeLa cell lysates can be used as a positive control.
Formulation
5.0 mg/mL by UV absorbance at 280 nm
0.02 M Potassium Phosphate, 0.15 M Sodium Chloride, pH 7.2
0.01% (w/v) Sodium Azide
None
100 µL
Restore with deionized water (or equivalent)
Shipping & Handling
Ambient
Store vial at 4° C prior to restoration. For extended storage aliquot contents and freeze at -20° C or below. Avoid cycles of freezing and thawing. Centrifuge product if not completely clear after standing at room temperature. This product is stable for several weeks at 4° C as an undiluted liquid. Dilute only prior to immediate use.
Expiration date is one (1) year from date of receipt.
Ubiquitin-like proteins fall into two classes: the first class, ubiquitin-like modifiers (UBLs) function as modifiers in a manner analogous to that of ubiquitin. Examples of UBLs are SUMO, Rub1 (also called Nedd8), Apg8 and Apg12. Proteins of the second class include parkin, RAD23 and DSK2, are designated ubiquitin-domain proteins (UDPs). These proteins contain domains that are related to ubiquitin but are otherwise unrelated to each other. In contrast to UBLs, UDPs are not conjugated to other proteins. ISG15 (Interferon Stimulating Gene-15) shows no amino acid sequence homology to cytokines and is synthesized as a precursor that is activated through processing by a thiol protease. ISG15 is secreted by monocytes and lymphocytes. Synthesis is induced in response to IFN-a or IFN-b or IFN-¥, but not IFN-g. ISG15 expression is induced also by overexpression of some interferon regulatory factors that have been shown to play a role in the transcriptional regulation of IFN genes. ISG15 is secreted also by cell lines of monocyte (U937 cell line), T-lymphocyte, B-lymphocyte (DAUDI cells), human fibroblasts, and epithelial origins. The induction of terminal differentiation in human melanoma cells is associated, among other things, with alterations in the expression of ISG15. Intracellularly ISG15 has been shown to function as a ubiquitin homologue. It is known also as UCRP (ubiquitin cross-reactive protein). Serpin 2a (spi2a), a member of the serine protease inhibitor (serpin) protein family that is highly induced in macrophages during bacillus Calmette-Guerin infection has been shown to bind ISG15. ISG15 has been shown to modulate immune cell function. It possesses activities of cytokines and induces production of IFN-g. It enhances proliferation and functions of natural killer and LAK cells.
Hsu JCC et al. (2021). Translational shutdown and evasion of the innate immune response by SARS-CoV-2 NSP14 protein. Proc Natl Acad Sci USA
Applications
WB, IB, PCA
Gall et al. (2018). Emerging Alphaviruses Are Sensitive to Cellular States Induced by a Novel Small-Molecule Agonist of the STING Pathway. Journal of Virology
Applications
WB, IB, PCA
Ezzati et al. (2015). Comparative proteomic analyses demonstrate enhanced interferon and STAT-1 activation in reovirus T3D-infected HeLa cells. Frontiers in Cellular and Infection Microbiology
Applications
WB, IB, PCA
Berard AR et al. (2015). Comparative proteomic analyses of two reovirus T3D subtypes and comparison to T1L identifies multiple novel proteins in key cellular pathogenic pathways. Proteomics.
Applications
WB, IB, PCA
Coombs KM et al. (2013). HeLa cell response proteome alterations induced by mammalian reovirus T3D infection. Virol J.
Applications
WB, IB, PCA
Fields J et al. (2013). Alterations in the levels of vesicular trafficking proteins involved in HIV replication in the brains and CSF of patients with HIV-associated neurocognitive disorders. J Neuroimmune Pharmacol.
Applications
WB, IB, PCA
Berard AR et al. (2012). Quantification of the host response proteome after mammalian reovirus T1L infection. PLoS One.
Applications
WB, IB, PCA
Loch CM et al. (2010). Deubiquitylase, deSUMOylase, and deISGylase activity microarrays for assay of substrate preference and functional modifiers. Mol Cell Proteomics.
Applications
Other
This product is for research use only and is not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information. All products of animal origin manufactured by Rockland Immunochemicals are derived from starting materials of North American origin. Collection was performed in United States Department of Agriculture (USDA) inspected facilities and all materials have been inspected and certified to be free of disease and suitable for exportation. All properties listed are typical characteristics and are not specifications. All suggestions and data are offered in good faith but without guarantee as conditions and methods of use of our products are beyond our control. All claims must be made within 30 days following the date of delivery. The prospective user must determine the suitability of our materials before adopting them on a commercial scale. Suggested uses of our products are not recommendations to use our products in violation of any patent or as a license under any patent of Rockland Immunochemicals, Inc. If you require a commercial license to use this material and do not have one, then return this material, unopened to: Rockland Inc., P.O. BOX 5199, Limerick, Pennsylvania, USA.